Merck's Keytruda Meets Main Endpoints in Esophageal Cancer Study
August 19 2020 - 7:38AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Wednesday said its cancer drug Keytruda met
its primary endpoints in a Phase 3 study in esophageal cancer.
The Kenilworth, N.J., drug maker said Keytruda in combination
with chemotherapy showed a statistically significant and clinically
meaningful improvement in overall survival and progression-free
survival versus chemotherapy alone as the first-line treatment of
patients with locally advanced or metastatic esophageal cancer.
Merck said the study also met the key secondary endpoint of
objective response rate, adding that Keytruda's safety profile was
consistent with that observed in previously studies.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, has been approved in several indications in
numerous cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 19, 2020 07:23 ET (11:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024